NRNP 6635 PSYCHOPATHOLOGY MIDTERM EXAM
2026/2027 | Diagnostic Reasoning | Walden University |
Verified Q&A | Pass Guaranteed - A+ Graded
Section 1: Neurobiology & Genetic Foundations (Q1-18)
Q1. Which dopamine pathway, when hyperactive, is most implicated in the
positive symptoms of schizophrenia?
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway
Correct Answer: C
Rationale: The mesolimbic pathway (projecting from the ventral tegmental area to
the nucleus accumbens and limbic structures) is hyperactive in schizophrenia,
producing positive symptoms (hallucinations, delusions). The mesocortical pathway
(A) is hypoactive, causing negative symptoms. The nigrostriatal pathway (B) is
associated with extrapyramidal side effects, and the tuberoinfundibular pathway (D)
regulates prolactin.
Q2. A 28-year-old patient with treatment-resistant depression is being evaluated
for genetic biomarkers. Which serotonin transporter gene polymorphism is
associated with differential response to SSRIs?
A. DRD2 Taq1A
B. 5-HTTLPR (SLC6A4)
,C. COMT Val158Met
D. CYP2D6 *4/*4
Correct Answer: B
Rationale: The 5-HTTLPR polymorphism in the SLC6A4 gene (serotonin transporter)
influences SSRI response, with the short (s) allele associated with poorer response
and increased side effects. DRD2 (A) relates to dopamine receptors, COMT (C) to
dopamine metabolism, and CYP2D6 (D) to drug metabolism rather than direct
biomarker prediction of antidepressant efficacy.
Q3. Which neurotransmitter system is primarily responsible for the therapeutic
effects of benzodiazepines in panic disorder?
A. Dopaminergic (D2 receptors)
B. Serotonergic (5-HT1A receptors)
C. GABAergic (GABA-A receptors)
D. Glutamatergic (NMDA receptors)
Correct Answer: C
Rationale: Benzodiazepines enhance GABA-A receptor function by increasing
chloride ion conductance, producing anxiolytic effects. While serotonin (B) is involved
in SSRI mechanisms for panic disorder, benzodiazepines act directly on the GABA-A
receptor complex (C). Dopamine (A) and glutamate (D) are not primary targets of
benzodiazepine action.
Q4. In the context of Alzheimer's disease pathophysiology, which receptor
subtype is primarily affected by the loss of cholinergic neurons in the nucleus
basalis of Meynert?
A. Muscarinic M1 receptors
B. Nicotinic receptors
C. Muscarinic M2 receptors
,D. Both muscarinic and nicotinic receptors, with nicotinic loss being most clinically
significant
Correct Answer: D
Rationale: The cholinergic hypothesis of Alzheimer's disease involves degeneration
of neurons in the nucleus basalis of Meynert, leading to deficits in both muscarinic
and nicotinic acetylcholine receptors. Nicotinic receptor loss (particularly α7 and
α4β2 subtypes) is especially significant for cognitive impairment. Options A, B, and C
each identify only one component of the broader cholinergic deficit.
Q5. Which norepinephrine receptor subtype is primarily responsible for the
peripheral autonomic symptoms (tachycardia, hypertension) seen in acute
stimulant intoxication?
A. α1-adrenergic receptors
B. α2-adrenergic receptors
C. β1-adrenergic receptors
D. β2-adrenergic receptors
Correct Answer: A
Rationale: α1-adrenergic receptors mediate vasoconstriction and contribute to
hypertension in stimulant intoxication. While β1 (C) increases heart rate and α2 (B)
modulates NE release, the peripheral pressor effects are primarily α1-mediated. β2
receptors (D) cause vasodilation and bronchodilation, not the pressor response.
Q6. A patient with bipolar disorder has a first-degree relative with schizophrenia.
Which shared genetic vulnerability locus has been identified in genome-wide
association studies (GWAS) for both disorders?
A. CACNA1C (calcium channel gene)
B. HTT (huntingtin gene)
C. APOE ε4
D. HLA-B27
, Correct Answer: A
Rationale: CACNA1C, which encodes the alpha-1C subunit of L-type calcium
channels, is a shared susceptibility locus for bipolar disorder, schizophrenia, and
major depression in GWAS. HTT (B) is associated with Huntington's disease, APOE ε4
(C) with Alzheimer's disease, and HLA-B27 (D) with autoimmune disorders, not
psychiatric conditions.
Q7. Which glutamate receptor subtype is the primary target of memantine in the
treatment of moderate-to-severe Alzheimer's disease?
A. AMPA receptors
B. Kainate receptors
C. NMDA receptors (uncompetitive antagonist)
D. Metabotropic glutamate receptors (mGluR5)
Correct Answer: C
Rationale: Memantine is an uncompetitive, low-affinity NMDA receptor antagonist
that blocks pathological glutamate excitotoxicity while preserving physiological
NMDA signaling. It does not primarily target AMPA (A), kainate (B), or mGluR5 (D)
receptors.
Q8. The therapeutic mechanism of vortioxetine in major depressive disorder
involves modulation of which serotonin receptor subtype that is thought to
enhance cognitive function?
A. 5-HT1A (partial agonist)
B. 5-HT2A (antagonist)
C. 5-HT3 (antagonist)
D. 5-HT7 (antagonist)
Correct Answer: A
Rationale: Vortioxetine is a multimodal antidepressant with 5-HT3, 5-HT7, and 5-
HT1D antagonism, 5-HT1B partial agonism, and 5-HT1A partial agonism. The 5-HT1A
2026/2027 | Diagnostic Reasoning | Walden University |
Verified Q&A | Pass Guaranteed - A+ Graded
Section 1: Neurobiology & Genetic Foundations (Q1-18)
Q1. Which dopamine pathway, when hyperactive, is most implicated in the
positive symptoms of schizophrenia?
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway
Correct Answer: C
Rationale: The mesolimbic pathway (projecting from the ventral tegmental area to
the nucleus accumbens and limbic structures) is hyperactive in schizophrenia,
producing positive symptoms (hallucinations, delusions). The mesocortical pathway
(A) is hypoactive, causing negative symptoms. The nigrostriatal pathway (B) is
associated with extrapyramidal side effects, and the tuberoinfundibular pathway (D)
regulates prolactin.
Q2. A 28-year-old patient with treatment-resistant depression is being evaluated
for genetic biomarkers. Which serotonin transporter gene polymorphism is
associated with differential response to SSRIs?
A. DRD2 Taq1A
B. 5-HTTLPR (SLC6A4)
,C. COMT Val158Met
D. CYP2D6 *4/*4
Correct Answer: B
Rationale: The 5-HTTLPR polymorphism in the SLC6A4 gene (serotonin transporter)
influences SSRI response, with the short (s) allele associated with poorer response
and increased side effects. DRD2 (A) relates to dopamine receptors, COMT (C) to
dopamine metabolism, and CYP2D6 (D) to drug metabolism rather than direct
biomarker prediction of antidepressant efficacy.
Q3. Which neurotransmitter system is primarily responsible for the therapeutic
effects of benzodiazepines in panic disorder?
A. Dopaminergic (D2 receptors)
B. Serotonergic (5-HT1A receptors)
C. GABAergic (GABA-A receptors)
D. Glutamatergic (NMDA receptors)
Correct Answer: C
Rationale: Benzodiazepines enhance GABA-A receptor function by increasing
chloride ion conductance, producing anxiolytic effects. While serotonin (B) is involved
in SSRI mechanisms for panic disorder, benzodiazepines act directly on the GABA-A
receptor complex (C). Dopamine (A) and glutamate (D) are not primary targets of
benzodiazepine action.
Q4. In the context of Alzheimer's disease pathophysiology, which receptor
subtype is primarily affected by the loss of cholinergic neurons in the nucleus
basalis of Meynert?
A. Muscarinic M1 receptors
B. Nicotinic receptors
C. Muscarinic M2 receptors
,D. Both muscarinic and nicotinic receptors, with nicotinic loss being most clinically
significant
Correct Answer: D
Rationale: The cholinergic hypothesis of Alzheimer's disease involves degeneration
of neurons in the nucleus basalis of Meynert, leading to deficits in both muscarinic
and nicotinic acetylcholine receptors. Nicotinic receptor loss (particularly α7 and
α4β2 subtypes) is especially significant for cognitive impairment. Options A, B, and C
each identify only one component of the broader cholinergic deficit.
Q5. Which norepinephrine receptor subtype is primarily responsible for the
peripheral autonomic symptoms (tachycardia, hypertension) seen in acute
stimulant intoxication?
A. α1-adrenergic receptors
B. α2-adrenergic receptors
C. β1-adrenergic receptors
D. β2-adrenergic receptors
Correct Answer: A
Rationale: α1-adrenergic receptors mediate vasoconstriction and contribute to
hypertension in stimulant intoxication. While β1 (C) increases heart rate and α2 (B)
modulates NE release, the peripheral pressor effects are primarily α1-mediated. β2
receptors (D) cause vasodilation and bronchodilation, not the pressor response.
Q6. A patient with bipolar disorder has a first-degree relative with schizophrenia.
Which shared genetic vulnerability locus has been identified in genome-wide
association studies (GWAS) for both disorders?
A. CACNA1C (calcium channel gene)
B. HTT (huntingtin gene)
C. APOE ε4
D. HLA-B27
, Correct Answer: A
Rationale: CACNA1C, which encodes the alpha-1C subunit of L-type calcium
channels, is a shared susceptibility locus for bipolar disorder, schizophrenia, and
major depression in GWAS. HTT (B) is associated with Huntington's disease, APOE ε4
(C) with Alzheimer's disease, and HLA-B27 (D) with autoimmune disorders, not
psychiatric conditions.
Q7. Which glutamate receptor subtype is the primary target of memantine in the
treatment of moderate-to-severe Alzheimer's disease?
A. AMPA receptors
B. Kainate receptors
C. NMDA receptors (uncompetitive antagonist)
D. Metabotropic glutamate receptors (mGluR5)
Correct Answer: C
Rationale: Memantine is an uncompetitive, low-affinity NMDA receptor antagonist
that blocks pathological glutamate excitotoxicity while preserving physiological
NMDA signaling. It does not primarily target AMPA (A), kainate (B), or mGluR5 (D)
receptors.
Q8. The therapeutic mechanism of vortioxetine in major depressive disorder
involves modulation of which serotonin receptor subtype that is thought to
enhance cognitive function?
A. 5-HT1A (partial agonist)
B. 5-HT2A (antagonist)
C. 5-HT3 (antagonist)
D. 5-HT7 (antagonist)
Correct Answer: A
Rationale: Vortioxetine is a multimodal antidepressant with 5-HT3, 5-HT7, and 5-
HT1D antagonism, 5-HT1B partial agonism, and 5-HT1A partial agonism. The 5-HT1A
